Skip to Main Content

Author Details

Uma Borate
The Ohio State University
2008
53
19
PMIDPaper TitleJournal TitlePublished Year
37871309A study to assess the efficacy of enasidenib and risk-adapted addition of azacitidine in newly diagnosed IDH2-mutant AML.Blood Adv2024
37994196Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes.Am J Hematol2024
36222845Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.Cancer Discov2023
37635639Real-world genomic testing and treatment patterns of newly diagnosed adult acute myeloid leukemia patients within a comprehensive health system.Cancer Med2023
37704469Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): A state-of-the-art report on behalf of the International Consortium for MDS (icMDS).Blood Rev2023
37078412Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial.Cancer2023
37341779Correction to: Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.Ann Hematol2023
36724453Consensus proposal for revised International Working Group 2023 response criteria for higher-risk myelodysplastic syndromes.Blood2023
36934059Current landscape of translational and clinical research in myelodysplastic syndromes/neoplasms (MDS): Proceedings from the 1<sup>st</sup> International Workshop on MDS (iwMDS) Of the International Consortium for MDS (icMDS).Blood Rev2023
36732419Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States.Ann Hematol2023
36315007Pevonedistat with azacitidine in older patients with TP53-mutated AML: a phase 2 study with laboratory correlates.Blood Adv2023
36309981A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.Am J Hematol2023
36260702An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS.Blood Adv2023
34482403Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.Blood2022
36485141New investigational combinations for higher-risk MDS.Hematology Am Soc Hematol Educ Program2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
36266326Finding consistency in classifications of myeloid neoplasms: a perspective on behalf of the International Workshop for Myelodysplastic Syndromes.Leukemia2022
35924860Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States: a retrospective claims database study.Expert Rev Hematol2022
35130502NCCN Guidelines® Insights: Myelodysplastic Syndromes, Version 3.2022.J Natl Compr Canc Netw2022
35028826Multidisciplinary Approach to Older Adults with Hematologic Malignancies-a Paradigm Shift.Curr Hematol Malig Rep2022
33997942Streamlined Operational Approaches and Use of e-Technologies in Clinical Trials: Beat Acute Myeloid Leukemia Master Trial.Ther Innov Regul Sci2021
33755090Azacitidine maintenance after allogeneic hematopoietic cell transplantation for MDS and AML.Blood Adv2021
33777461CNS Involvement in a Patient with Chronic Myeloid Leukemia.Case Rep Hematol2021
34162404A precision medicine classification for treatment of acute myeloid leukemia in older patients.J Hematol Oncol2021
32754299Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.Oncotarget2020
33106665Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial.Nat Med2020
30694839Novel Approaches for Systemic Mastocytosis.Curr Opin Hematol2019
31816063Patients with FLT3-mutant AML needed to enroll on FLT3-targeted therapeutic clinical trials.Blood Adv2019
31537526Representation of therapy-related myelodysplastic syndrome in clinical trials over the past 20 years.Blood Adv2019
30836091Allogeneic transplantation outcomes amongst a contemporary cohort of high-risk myelodysplastic syndrome and acute myeloid leukemia patients aged â¿¥70 years.Hematol Oncol Stem Cell Ther2019
29048112How we diagnose and treat systemic mastocytosis in adults.Br J Haematol2018
30082821Dual inhibition of JAK1/2 kinases and BCL2: a promising therapeutic strategy for acute myeloid leukemia.Leukemia2018
30139831Applicability of the AML knowledge bank approach.Blood2018
30551737Implementing a comprehensive translational oncology platform: from molecular testing to actionability.J Transl Med2018
30333627Functional genomic landscape of acute myeloid leukaemia.Nature2018
29390159Improving shared decision-making in chronic lymphocytic leukemia through multidisciplinary education.Transl Behav Med2018
28181280Identification of targeted therapies for rare adult mature T-cell leukemia using functional ex vivo screening of primary patient samples.Am J Hematol2017
26882103Reply to a note on the magnitude of hazard ratios.Cancer2016
29046900US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.Blood Adv2016
26994848Treatment of CD30-positive systemic mastocytosis with brentuximab vedotin.Leuk Res2016
25736003Myelodysplastic syndromes, version 2.2015.J Natl Compr Canc Netw2015
26483064Acute Lymphoblastic Leukemia, Version 2.2015.J Natl Compr Canc Netw2015
26259760Therapy-related B-lymphoblastic leukemia associated with Philadelphia chromosome and MLL rearrangement: Single institution experience and the review of the literature.Pathol Int2015
26367383Nonbiological factors affecting survival in younger patients with acute myeloid leukemia.Cancer2015
25209604Clinicopathological and molecular features of myeloid sarcoma as initial presentation of therapy-related myeloid neoplasms: a single institution experience.Int J Hematol2014
22890287A cautionary tale for probiotic use in hematopoietic SCT patients-Lactobacillus acidophilus sepsis in a patient with mantle cell lymphoma undergoing hematopoietic SCT.Bone Marrow Transplant2013
23847220Myelodysplastic syndromes: clinical practice guidelines in oncology.J Natl Compr Canc Netw2013
24029121Acute myeloid leukemia, version 2.2013.J Natl Compr Canc Netw2013
22800091Examining racial differences in diffuse large B-cell lymphoma presentation and survival.Leuk Lymphoma2013
22878824NCCN Clinical Practice Guidelines Acute myeloid leukemia.J Natl Compr Canc Netw2012
  • 1 - 50 of 53

Recommended Authors

Lohith Gowda
Yale Cancer Center and Yale School of Medicine
Career Start Year 2018
Number of shared co-authors 3
Shalin Kothari
Yale University
Career Start Year 2013
Number of shared co-authors 2
Hein Than
Singapore General Hospital
Career Start Year 2012
Number of shared co-authors 28
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 3
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 0
Friedrich St??lzel
University Hospital TU Dresden
Career Start Year 2008
Number of shared co-authors 6
Thomas K??hnke
Cancer Institute, Stanford University School of Medicine
Career Start Year 2008
Number of shared co-authors 7
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 4
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 23
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 1
Felicitas Thol
Hannover Medical School
Career Start Year 2007
Number of shared co-authors 14
Rashmi Kanagal-Shamanna
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 8
Thomas Cluzeau
Universite Nice Cote d'azur, CHU de Nice
Career Start Year 2005
Number of shared co-authors 5
Marlise R Luskin
Dana-Farber Cancer Institute
Career Start Year 2005
Number of shared co-authors 32
Raphael Itzykson
Universite Paris Cite, INSERM, CNRS
Career Start Year 2004
Number of shared co-authors 7
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 8
Naseema Gangat
Mayo Clinic
Career Start Year 2004
Number of shared co-authors 9
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 3
Christoph R??llig
Hopp Children's Cancer Center (KiTZ)
Career Start Year 2000
Number of shared co-authors 11
Todd A Alonzo
Keck School of Medicine, University of Southern California
Career Start Year 1999
Number of shared co-authors 7
Emmanuel Raffoux
Universite Paris Diderot
Career Start Year 1998
Number of shared co-authors 8
Nikolas von Bubnoff
University Hospital of Schleswig-Holstein
Career Start Year 1997
Number of shared co-authors 4
David A Rizzieri
Duke University Medical Center
Career Start Year 1995
Number of shared co-authors 19
Michael Heuser
Hannover Medical School
Career Start Year 1993
Number of shared co-authors 17
Gautam Borthakur
MD Anderson Cancer Center
Career Start Year 1992
Number of shared co-authors 29
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 6
Jorge Cortes
Georgia Cancer Center
Career Start Year 1991
Number of shared co-authors 47
Claude Gardin
Avicenne Hospital
Career Start Year 1990
Number of shared co-authors 1
Jason Gotlib
Stanford University School of Medicine
Career Start Year 1989
Number of shared co-authors 52
Herv?? Dombret
Institut de Recherche Saint-Louis, Universite de Paris
Career Start Year 1984
Number of shared co-authors 9

Collaborators

Brian J Druker
Oregon Health & Science University
Co-authored papers 11
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 7
Christopher S Hourigan
and Blood Institute, National Institutes of Health
Co-authored papers 7
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 7
Prapti Patel
The University of Texas Southwestern Medical Center
Co-authored papers 6
Jeffrey W Tyner
Oregon Health & Science University School of Medicine
Co-authored papers 6
Richard M Stone
Dana Farber Cancer Institute
Co-authored papers 6
Guillermo Garcia-Manero
MD Anderson Cancer Center
Co-authored papers 6
Elie Traer
Oregon Health & Science University
Co-authored papers 6
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 6
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 5
Rafael Bejar
Moores Cancer Center, university of california san diego
Co-authored papers 5
Tara L Lin
University of Kansas Medical Center
Co-authored papers 5
David P Steensma
Novartis Institutes for BioMedical Research
Co-authored papers 5
Ravindra Majeti
Stanford University School of Medicine
Co-authored papers 4
John T Schiller
David Geffen School of Medicine at university of california los angeles
Co-authored papers 4
Stephanie Halene
Smilow Cancer Center, Yale University School of Medicine
Co-authored papers 4
Motomi Mori
St Jude Children's Research Hospital.
Co-authored papers 4
Nicola Long
Oregon Health and Science University
Co-authored papers 3
Farhad Ravandi
University of Texas M.D. Anderson Cancer Center
Co-authored papers 3
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 3
Ronan Swords
Oregon Health and Science University
Co-authored papers 3
Stephen E Spurgeon
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 3
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Kim-Hien T Dao
Astex Pharmaceuticals
Co-authored papers 3
Martin S Tallman
Memorial Sloan-Kettering Cancer Center
Co-authored papers 3
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Pierrette Lo
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 3
Jessica Leonard
Oregon Health & Science University
Co-authored papers 3
Release 1.2